Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?

Oncology Reports

Volumn 14, Issue 4, 2005, Pages 1077-1081

  Odrazka, Karel ^a   Vaculikova, Miloslava ^a   Dolezel, Martin ^a   Petera, Jiri ^a   Moravek, Petr ^a   Prosvic, Petr ^a   Zoul, Zdenek ^a   Vosmik, Milan ^a   Dolezal, Jiri ^a   Simakova, Eva ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Carboplatin; Docetaxel; Hormone refractory prostate cancer; Second line chemotherapy; Vinblastine

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CARBOPLATIN; DEXAMETHASONE; EPIRUBICIN; ETOPOSIDE; HORMONE; PROSTATE SPECIFIC ANTIGEN;

AGED; AREA UNDER THE CURVE; ARTICLE; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; DRUG RESISTANCE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PROSTATE TUMOR; THROMBOCYTOPENIA; TIME; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; DEXAMETHASONE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; ETOPOSIDE; HORMONES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 33644824529     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.4.1077     Document Type: Article

References (17)

1. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME and Bubley GJ: High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 159: 149-153, 1998. (Pubitemid 27525592)
2. Petrylak DP, Tangen C, Hussain M, Lara PN, Jones J, Talpin ME, Burch P, Greene G, Small E and Crawford ED: SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (P) in men with androgen-independent prostate cancer (AIPCA). J Clin Oncol 22 (suppl 14): 3, 2004.
3. Eisenberger MA, De Wit R, Berry W, Bodrogi I, Pluzanska A, Chi K, Oudard S, Christine T, James N and Tannock I: A multicenter phase III comparison of docetaxel (D) + prednison (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). J Clin Oncol 22 (suppl 14): 4, 2004.
4. Rosenberg JE and Small EJ: Second-line chemotherapy for hormone-refractory prostate cancer: has the time come? Clin Prostate Cancer 3: 122-124, 2004. (Pubitemid 39403231)
5. Urakami S, Yoshino T, Kikuno N, Imai S, Honda S, Yoneda T, Kishi H, Shigeno K, Shiina H and Igawa M: Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study. Urology 65: 543-548, 2005. (Pubitemid 40386006)
6. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981. (Pubitemid 11167383)
7. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
8. Arduino LJ and Mellinger GT: Clinical trial of busulfan (NSC-750) in advanced carcinoma of prostate. Cancer Chemother Rep 51: 295-303, 1967.
9. Pavone Macaluso M, Caramia G and Vecchioni M: Antiblastic chemotherapy in the treatment of cancer of the prostate. J Urol Nephrol 78: 621-634, 1972.
10. Ellerhorst JA, Tu SM, Amato RJ, Finn L, Millikan RE, Pagliaro LC, Jackson A and Logothetis CJ: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3: 2371-2376, 1997. (Pubitemid 28133157)
11. Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ and Vogelzang NJ: Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol 19: 2509-2516, 2001. (Pubitemid 32391222)
12. Small EJ, Apodaca D and Baron A: Second-line chemotherapy with doxorubicin/cyclophosphamide (DOX/CY) for hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 16: 343a, 1997.
13. Gomes F, Marques A and Oliveira F: Docetaxel with estramustine in hormone-independent prostate cancer (AIPC) as second line chemotherapy. Ann Oncol 13 (suppl 5): 95, 2002.
14. Goodin S, Rao KV, Engle EA, Kane M, Capanna T, Ciardella M, Todd MB and DiPaola RS: A phase II study of docetaxel and vinorelbine in hormone refractory prostate cancer (HRPC) with and without prior chemotherapy. Proc Am Soc Clin Oncol 21: 161b, 2002.
15. Jungi WF, Bernhard J, Hurny C, Schmitz SF, Hanselmann S, Gusset H, Pestalozzi D and Goldhirsch A: Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK). Support Care Cancer 6: 462-468, 1998. (Pubitemid 28433402)
16. Dexeus F, Logothetis CJ, Samuels ML, Hossan E and von Eschenbach AC: Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep 69: 885-886, 1985. (Pubitemid 15229432)
17. Karavasilis V, Briasoulis E, Siarabi O and Pavlidis N: Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: pilot study of an effective subtoxic therapy. Clin Prostate Cancer 2: 46-49, 2003. (Pubitemid 37012421)